Compare GAB & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GAB | NEO |
|---|---|---|
| Founded | 1986 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.1B |
| IPO Year | N/A | 2008 |
| Metric | GAB | NEO |
|---|---|---|
| Price | $5.59 | $17.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $13.38 |
| AVG Volume (30 Days) | 593.1K | ★ 1.5M |
| Earning Date | 01-01-0001 | 04-28-2026 |
| Dividend Yield | ★ 10.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.63 |
| Revenue Next Year | N/A | $9.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.28 | $7.07 |
| 52 Week High | $6.37 | $19.76 |
| Indicator | GAB | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 40.99 | 58.79 |
| Support Level | $5.46 | $15.72 |
| Resistance Level | $5.75 | $19.76 |
| Average True Range (ATR) | 0.05 | 0.84 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 0.00 | 36.90 |
Gabelli Equity Trust Inc is a non-diversified closed-end management investment company. Its primary investment objective is the long-term growth of capital with income as a secondary objective. The Fund invests at least its assets in equity securities under normal market conditions. Its equity portfolio includes common stock, preferred stock, convertible or exchangeable securities, and warrants and rights to purchase such securities selected by the Investment Adviser. The company invests in various sectors, of which Food & Beverage, Financial Services, Equipment and Supplies, Entertainment, Consumer Products, Health Care, Diversified Industrial, Business Services, Consumer Services and others.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.